France Oncology Companion Diagnostic Market Size & Outlook

The oncology companion diagnostic market in France is expected to reach a projected revenue of US$ 276.3 million by 2030. A compound annual growth rate of 9.2% is expected of France oncology companion diagnostic market from 2025 to 2030.
Revenue, 2024 (US$M)
$165.5
Forecast, 2030 (US$M)
$276.3
CAGR, 2025 - 2030
9.2%
Report Coverage
France

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

France oncology companion diagnostic market, 2018-2030 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

France oncology companion diagnostic market highlights

  • The France oncology companion diagnostic market generated a revenue of USD 154.4 million in 2023 and is expected to reach USD 276.3 million by 2030.
  • The France market is expected to grow at a CAGR of 8.7% from 2024 to 2030.
  • In terms of segment, product was the largest revenue generating product & service in 2023.
  • Service is the most lucrative product & service segment registering the fastest growth during the forecast period.

Oncology companion diagnostic market data book summary

Market revenue in 2023USD 154.4 million
Market revenue in 2030USD 276.3 million
Growth rate8.7% (CAGR from 2024 to 2030)
Largest segmentProduct
Fastest growing segmentService
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationProduct, Service
Key market players worldwideAgilent Technologies Inc, Illumina Inc, Qiagen NV, Thermo Fisher Scientific Inc, ARUP Laboratories, Abbott Laboratories, Myriad Genetics Inc, BioMerieux SA, Roche Holding AG ADR

Other key industry trends

  • In terms of revenue, France accounted for 3.2% of the global oncology companion diagnostic market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Europe, Germany oncology companion diagnostic market is projected to lead the regional market in terms of revenue in 2030.
  • Germany is the fastest growing regional market in Europe and is projected to reach USD 497.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Oncology Companion Diagnostic Market Companies

Name Profile # Employees HQ Website
ARUP Laboratories View profile 1001-5000 Salt Lake City, Utah, United States, North America http://www.aruplab.com
Myriad Genetics Inc View profile 2700 320 Wakara Way, Salt Lake City, UT, United States, 84108 https://www.myriad.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Agilent Technologies Inc View profile 17700 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 https://www.agilent.com
Illumina Inc View profile 9300 5200 Illumina Way, San Diego, CA, United States, 92122 https://www.illumina.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
BioMerieux SA View profile 13982 Marcy l’Etoile, Lyon, France, 69280 http://www.biomerieux.com
Abbott Laboratories View profile 114000 100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400 https://www.abbottinvestor.com
Roche Holding AG ADR View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com

France oncology companion diagnostic market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology companion diagnostic market will help companies and investors design strategic landscapes.


Product was the largest segment with a revenue share of 66.52% in 2024. Horizon Databook has segmented the France oncology companion diagnostic market based on product, service covering the revenue growth of each sub-segment from 2018 to 2030.


Companies and research institutes are entering several unique partnerships to offer in-house CDx genomic testing for cancer patients in France, significantly enhancing market growth by improving diagnostic precision and personalized treatment options.


For instance, in September 2023, Foundation Medicine, Inc., Roche France, and the Institute Gustave Roussy have entered a strategic partnership to transfer technology from Foundation Medicine's FoundationOne Liquid CDx, a blood-based Comprehensive Genomic Profiling (CGP) test, to establish in-house liquid biopsy testing at the Institute Gustave Roussy's facilities in France.


As part of this public-private collaboration, the Institute Gustave Roussy will expand its biopathology capabilities by creating an innovative laboratory for genomic testing, working in coordination with leading precision medicine experts, centers, and institutions across France.

Reasons to subscribe to France oncology companion diagnostic market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of France oncology companion diagnostic market databook

  • Our clientele includes a mix of oncology companion diagnostic market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the France oncology companion diagnostic market , including forecasts for subscribers. This country databook contains high-level insights into France oncology companion diagnostic market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

France oncology companion diagnostics market size, by product & service, 2018-2030 (US$M)

France Oncology Companion Diagnostic Market Outlook Share, 2024 & 2030 (US$M)

France oncology companion diagnostics market size, by product & service, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online